Info

Omniviral Therapeutics (OVT), a biopharmaceutical company, is focused exclusively on the development and commercialization of proprietary, anti-viral therapies for the treatment of life-threatening infectious diseases including HIV/AIDS, influenza and hemorrhagic fevers. The Company's lead compound is an analog of cyanovirin-N (CVN), a potent, irreversible, viral neutralizing protein discovered at the US National Cancer Institute (NCI). OVT has worldwide licenses from the National Institutes of Health (NIH) to key patents and patent applications pertaining to the development and commercialization of CVN and its analogs for various fields of use including therapeutics for HIV/AIDS, influenza, and hemorrhagic fevers. Pre-clinical characterization of CVN and its analogs has demonstrated several distinct and compelling, potential competitive advantages over other anti-viral compounds currently marketed or in development for the treatment of HIV/AIDS.